Fri, Aug 29, 2014, 5:58 AM EDT - U.S. Markets open in 3 hrs 32 mins

Recent

% | $
Quotes you view appear here for quick access.

Watson Pharmaceuticals, Inc. Message Board

alexwv 1 post  |  Last Activity: Jun 23, 2014 9:44 PM Member since: Feb 3, 1998
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • CTIX DD-SP Catalysts
    Run coming with Brilicidin Defensin comparable or better than Cubists Daptomycyn trial results by middle end of July. Possible BTD if results match or beat Daptomycyn.

    "* Kevetrin Phase 1 entering 8th Cohort with no prior phase 1 limiting DLTs or MTD yet observed. Dosing now into the higher of the anticipated efficacy range. Cohort 8 215MG, 33% increase. Possible MTD by cohort 9/10

    * K in combination against renal completed most if not all preclinical work.

    * K in combination against leukemia (AML) already [completed] preclinical work at UofB and a Phase 1b/2 Clinical Trial is poised to start

    * K against Retinoblastoma announced in March 2013 will commence soon

    * Prurisol bridge study enrollment complete. Abracavir conversion will result in phase 2/3

    * B against ABSSSI now 70% enrolled and treated NO AE's.

    * B Review board meeting July

    * Large pharma discussions underway possible announcement after July review board meeting. Possible BTD on B after review meeting or by end of trial if results match or beat Daptomycyn

    * B OM completed final formulation work and expected to submit INDA to FDA.
    * B ocular formulation studies underway at Dr Reddy's and should complete within the next few to 6 months.
    * B otic also in formulation studies at Dr Reddy's
    * B DFI just announced high efficacy and should begin final preclinical work ahead of clinical testing. "
    *B NY/ NJ universities material transfer agreement defensive mimetics
    *Cellceutix in June, 2014, entered into a research agreement with a renowned non-profit research institution for studies of anti-fungal compounds in Cellceutix’s portfolio. The research is to be funded by a $1.5 million grant from the National Institute of Health, Small Business Innovation Research (SBIR) to the non-profit institution

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.